Autophagy represents a new frontier of drug development that utilizes the autophagosome to degrade disease driving targets. Casma’s internal and external team share the excitement of creating a new class of therapeutics with the potential to remove the causes of diseases and make a difference in the lives of patients.”

Keith Dionne, Ph.D.
Chief Executive Officer

The Autophagy/lysosome pathway is an essential cellular mechanism for maintaining cellular homeostasis. Its roles include degrading and clearing disease causing targets such as aggregated proteins, dysfunctional cellular organelles, large signaling complexes and invading bacteria or viruses for the preservation of cellular integrity by enhancing membrane repair through lysosomal membrane patching. Our classic understanding of the autophagy pathway as a response to nutrient starvation has dramatically evolved in recent years, with an explosion of technology defining selectivity, membrane dynamics, and lysosomal signaling responses. A vibrant research community and our own research provides us with the understanding to develop novel therapeutics to specifically capture disease causing targets, enhance lysosomal degradation and improve membrane integrity. Through these means, we are developing therapeutics to treat both broad and rare genetic illnesses that currently have no adequate remedy.

In Memoriam


Schroder Adveq

Schroder Adveq is a leading global private equity asset manager. With USD 10 billion in assets under management, Schroder Adveq focuses on specialized investment solutions that provides institutional clients access to select private market segments through primary, secondary and direct/co-investments.

Eventide Asset Management, LLC,

Eventide Asset Management, LLC, is a Boston-based investment adviser pursuing “investing that makes the world rejoice.®” Founded in 2008, Eventide’s vision is to serve individuals, financial advisors, and institutions by seeking to provide high-performing investments that we believe create compelling value for the global common good.

The Column Group

The Column Group is a science-driven venture capital firm that makes significant financial and operational commitments to build early stage drug discovery companies based on their unique scientific platforms and potential to deliver multiple breakthrough therapeutics. Our companies are built in bold pursuit of big ideas, using innovative science poised to have a profound impact on human health.

Third Rock

Third Rock Ventures is a leading health care venture firm focused on investing in, launching and building companies that make a difference in people’s lives. Third Rock collaborates closely with its strategic partners and entrepreneurs and has an extensive track record of managing value creation to deliver exceptional performance.


Casma Therapeutics has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). As the world’s largest nonprofit funder of Parkinson’s research, MJFF is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers.